Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine:: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials

被引:19
作者
Dahlöf, CG
Pascual, J
Dodick, DW
Dowson, AJ
机构
[1] Inst Clin Neurosci, Gothenburg Migraine Clin, S-41117 Gothenburg, Sweden
[2] Univ Hosp Marques Valdecilla, Serv Neurol, Santander, Spain
[3] Mayo Clin, Dept Neurol, Scottsdale, AZ USA
[4] Kings Coll Hosp London, Kings Headache Serv, London, England
关键词
almotriptan; meta-analysis; migraine; onset of action; efficacy; tolerability;
D O I
10.1111/j.1468-2982.2005.01080.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A meta-analysis of pooled individual patient data from four randomized, placebo-controlled, double-blind trials comparing several doses of almotriptan (n = 1908) with placebo (n = 386) was used to investigate the efficacy, speed of onset and tolerability of almotriptan in the acute treatment of migraine. As early as 30 min after dosing, almotriptan 12.5 mg was significantly more effective than placebo for pain relief (14.9% vs. 8.2%; P < 0.05) and pain free (2.5% vs. 0.7%; P < 0.05). At 2 h, pain-relief rates were 56.0%, 63.7% and 66.0% for almotriptan 6.25, 12.5 and 25 mg, respectively, compared with 35% for placebo; 2-h pain-free rates were 26.7%, 36.4% and 43.4% compared with 13.9% for placebo. All almotriptan dosages were significantly more effective than placebo in eliminating migraine-associated symptoms (P < 0.05) and in achieving sustained pain relief up to 24 h (P < 0.05). The incidence of adverse events after almotriptan 6.25 mg and 12.5 mg was not significantly different from that of placebo. This meta-analysis confirms the findings of individual clinical trials, while demonstrating for the first time, significant pain-free efficacy at 30 min compared with placebo.
引用
收藏
页码:400 / 408
页数:9
相关论文
共 27 条
[1]
CABARROCAS X, 1997, CEPHALALGIA, V17, P421
[2]
THE COMBINATION OF ESTIMATES FROM DIFFERENT EXPERIMENTS [J].
COCHRAN, WG .
BIOMETRICS, 1954, 10 (01) :101-129
[3]
Dahl?f C., 2004, J HEADACHE PAIN, V5, P115
[4]
Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine [J].
Dahlöf, C ;
Tfelt-Hansen, P ;
Massiou, H ;
Fazekas, A .
NEUROLOGY, 2001, 57 (10) :1811-1817
[5]
Determinants of patient satisfaction with migraine therapy [J].
Davies, GM ;
Santanello, N ;
Lipton, R .
CEPHALALGIA, 2000, 20 (06) :554-560
[6]
METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[7]
Advances in pharmacological treatment of migraine [J].
Diener, HC ;
Limmroth, V .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (10) :1831-1845
[8]
Dodick D W, 2001, Clin Cornerstone, V4, P36, DOI 10.1016/S1098-3597(01)90038-9
[9]
Almotriptan is an effective and well-tolerated treatment for migraine pain:: results of a randomized, double-blind, placebo-controlled clinical trial [J].
Dowson, AJ ;
Massiou, H ;
Laínez, JM ;
Cabarrocas, X .
CEPHALALGIA, 2002, 22 (06) :453-461
[10]
Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials [J].
Ferrari, MD ;
Loder, E ;
McCarroll, KA ;
Lines, CR .
CEPHALALGIA, 2001, 21 (02) :129-136